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ABSTRACT
The series of events that allow the conversion from adherent epithelial cells 
into migratory cells is collectively known as epithelial-mesenchymal transition 
(EMT). EMT is employed during embryonic development such as for gastrulation and 
neural crest migration and is misused in diseases, such as cancer metastasis. ERK 
signalling is known to be essential for EMT, however its influence on the epigenetic 
and transcriptional programme underlying EMT is poorly understood. Here, using 
a comprehensive genome-wide analysis of H3K27ac mark and gene expression in 
mammary epithelial cells undergoing EMT, we found that ERK signalling is essential 
for the epigenetic reprogramming underlying hallmark gene expression and 
phenotypic changes of EMT. We show that the chemical inhibition of Erk signalling 
during EMT prevents the loss and gain of the H3K27ac mark at regulatory regions of 
epithelial and mesenchymal genes, respectively, and results in a transcriptome and 
epigenome closer to those of epithelial cells. Further computational analyses identified 
a distinct set of transcription factor motifs enriched at distal regulatory regions that 
are epigenetically remodelled by ERK signalling. Altogether, our findings reveal an 
ERK-dependent epigenetic remodelling of regulatory elements that results in a gene 
expression programme essential for driving EMT.
INTRODUCTION
Epithelial to mesenchymal transition (EMT) is 
a process of phenotypic remodelling that enables cells 
to detach from their surroundings by losing cell-to-
cell connections and to subsequently migrate. Such 
an acquisition of a motile, mesenchymal phenotype 
involves cytoskeletal remodelling, changing of cellular 
shape and the resolution of cellular adhesion [1, 2]. 
EMT occurs primarily during embryonic development 
[1], tissue regeneration and wound healing [3, 4], and 
is also misused in disease conditions, such as fibrosis 
[5] and metastasis formation during tumorigenesis [6]. 
This process is primarily induced by cytokines, such as 
transforming growth factor β (TGF-β), which are secreted 
by the cells and stimulate several signalling cascades 
that result in phenotypic remodelling. The RAS–RAF–
MEK–ERK MAPK signalling cascade is one of such 
cascades that is known to be essential for the acquisition 
of a mesenchymal phenotype [7–9]. However, very little 
is known regarding the mechanism of ERK signalling 
action during EMT. Importantly, it is yet elusive how ERK 
signalling modulates EMT gene expression program and 
whether this involves modulation of the epigenome.
It is increasingly appreciated that a variety of 
signalling cascades involve remodelling of the chromatin 
landscape for the consequent translation of extracellular 
cues into the transcriptional response of the cell [10]. 
Such rearrangement of the epigenome may be achieved 
by signalling pathways targeting chromatin modifying 
enzymes, transcription factors and histone chaperones. 
In line with this, genome-wide analysis of chromatin 
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marks during TGF-β-induced EMT previously revealed 
a reorganization of specific chromatin domains in this 
process that involved an LSD1-dependent reduction of 
heterochromatic marks and an increase in euchromatic 
marks [11]. Interestingly, ERK was recently shown 
to phosphorylate MCRIP1, which in turn releases the 
transcriptional co-repressor CTBP to interact with Zeb1 at 
target gene promoters, such as E-cadherin, and represses 
transcription [12]. Furthermore, ERK is thought to 
modify chromatin by directly phosphorylating histones 
or inducing downstream factors such as MSK1, AuroraB 
and PKM2 that have been shown to modify histone 3 at 
serine 10 (H3S10) [13] [14] [15]. Moreover, there are also 
reports of a direct binding of ERK to chromatin in mouse 
and human embryonic stem cells [16] [17, 18]. However 
it is not explored whether ERK functions similarly via 
epigenome modulation during EMT. Therefore, we sought 
to elucidate the effects of ERK signalling cascade on 
chromatin and transcriptome landscape during EMT.
Here, we found that cells deficient in ERK signalling 
fail to undergo proper EMT. Using global gene expression 
profiling, we identified a significant set of epithelial 
and mesenchymal genes under the direct transcriptional 
control of the ERK signalling pathway. Importantly, 
we show that a large fraction of these gene expression 
changes can be explained by ERK-dependent epigenetic 
remodelling of their regulatory elements. These regulatory 
regions are enriched for distinct transcription factor motifs 
and provide candidate downstream effectors of the ERK 
pathway for further investigation.
RESULTS
ERK signalling is required for phenotypic 
remodelling during TGF-β-induced EMT
To address the dynamics of ERK signalling during 
EMT, we used untransformed normal murine mammary 
gland (NMuMG) epithelial cells exposed to TGF-β, which 
is an established model for EMT in cell culture [19, 20] 
(Figure 1A). Using this system, we first assessed the 
phosphorylation kinetics of the kinases Mapk1 (ERK2) 
and Mapk3 (ERK1) during TGF-β-induced EMT. An 
immunoblot analysis of the phosphorylated ERK isoforms 
during an EMT time-course experiment showed that while 
ERK phosphorylation was upregulated within 1 hour of 
EMT initiation, its first strong induction was observed at 
the 3 hours time point, which continued to show gradual 
increase until 24 hours (Figure 1B and 1C). Guided by 
this activation pattern of ERK signalling, we chemically 
inhibited the pathway at both an early (4h) and late (24h) 
time point of TGF-β-induced EMT. Following a defined 
treatment scheme using an established inhibitor of ERK 
signalling, UO126, 30 minutes before TGF-β induction 
(Figure 1D), we observed a significant blockage of ERK 
activation both at 4h and 24h (Figure 1E). The inhibition 
of the ERK signalling cascade perturbed the acquisition 
of the phenotypic changes observed after 24h of TGF-β 
induction (Figure 1F and Supplementary Figure 1A). 
Overall, these cells were less elongated, did not resolve 
cell-to-cell connections and appeared more similar to 
the untreated epithelial control cells (Figure 1F and 
Supplementary Figure 1A). This phenotypic observation 
from bright field images was strongly supported by 
immunofluorescence staining for key EMT markers 
(Figure 1G). The cell junction markers, including ZO-1, 
the epithelial cadherin Cdh1 as well as the mesenchymal 
cadherin Cdh2 lost their membrane-associated localization 
during EMT and displayed a more dispersed staining in 
the entire cytosol during EMT. However, they remained 
localized to the membrane in the cells treated with the 
ERK inhibitor, thus suggesting that the cells retained an 
epithelial phenotype (Figure 1G). These observations 
were further validated using an independent ERK 
inhibitor PD98095 (Supplementary Figure 1A and 1B). 
Furthermore, F-actin, which shows a distinct staining of 
the cellular membrane in untreated cells, forms stress 
fibres in the mesenchymal cells but stays membrane-
associated after the inhibition of ERK. Together, our 
findings indicate that ERK signalling is required for 
TGF-β-induced EMT, a conclusion in line with previous 
observations [7, 8].
Inhibition of ERK signalling results in an 
aberrant EMT gene expression program
Intrigued by the strong effect of ERK signalling 
on the phenotypic remodelling from an epithelial to 
mesenchymal state, we next sought to delineate the 
global transcriptional remodelling under the control of 
the ERK pathway. To this end we performed a genome-
wide expression analysis and compared cells undergoing 
TGF-β-induced EMT with cells having compromised 
ERK signalling at 4h and 24h after EMT induction. A 
two-dimensional principal component analysis (PCA) 
was used to determine the variation between the samples 
(Figure 2A). Interestingly, as cells underwent EMT, 
their transcriptomes consecutively diverges on both 
principal components, whereas the ERK-inhibited cells 
exhibited changes in the second principal component 
that became more similar to the untreated condition. 
This result suggests that these are the genes leading 
to phenotypic reversal. The transcriptome analysis 
between cells undergoing normal EMT and cells with 
compromised ERK signalling indicated a significant 
fraction of deregulated genes at the early time point (4h; 
up=217, down=341), with more pronounced changes at 
the late time point (24h; up=551, down=590) (Figure 2B 
and 2C). Genes that exhibited expression level changes 
during EMT in normal cells but not in ERK-inhibited cells 
include several epithelial genes, such as Nid2, Cdkn1a, 
Id2, Tjp3, Crb3 and Wnt4 (Figure 2D and 2E), and key 
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mesenchymal genes, such as Il11, Snai1, Hmga2, Ltbp1, 
Sox9 and Lamb1 (Figure 2F and 2G).
To comprehensively delineate which of the 
transcriptional changes induced during EMT (Figure 
2, Supplementary Figure 2) are dependent on ERK 
signalling, we chose the genes that were differentially 
expressed between both conditions at 4h of EMT, 
analysed their expression at both time points and plotted 
a k-means (k=5) clustered heatmap representing their 
expression (Figure 2H). Interestingly, we discovered 
three clusters of genes (Cluster 1, 2 and 4) that exhibited 
significantly altered expression during EMT and showed 
a transcriptional reversal towards the untreated condition 
after ERK inhibition (Figure 2I and Supplementary Figure 
1C); these genes likely explain the compromised potential 
to undergo EMT. Cluster 1 contained the genes that were 
downregulated during EMT but not after ERK signalling 
inhibition. Genes of this cluster were associated with gene 
ontology categories such as epithelium development and 
epithelial cell differentiation and included Shroom3, Id2, 
Gata5, Crb2 and Notch1 (Figure 2J cluster 1). Cluster 
4 contained the genes that were highly induced in the 
early stages of EMT but were not activated when ERK 
was inhibited. These genes were associated with gene 
ontology categories such as the regulation of cell motility, 
migration, locomotion and metabolic processes (Figure 
2J, cluster 4). They encode ligands, signalling molecules, 
receptors, chemotactic factors and integrins, such as 
Cx3cl1, Jak2, Tgfbr1, Ccl2 and Itga2, which are essential 
for the early cellular changes during EMT. Cluster 2 
contained the genes that were continuously upregulated 
during EMT, exhibiting the highest expression levels 
at 24h but were not upregulated in cells that displayed 
compromised ERK signalling. These genes were also 
Figure 1: Inhibition of ERK signalling impairs EMT. (A) EMT in mouse mammary epithelial cells (NMuMG) upon TGFβ 
treatment. (B) Representative immunoblots showing the phosphorylation state of ERK during TGF-β-induced EMT in NMuMG cells. 
GAPDH and total EKR are loading controls. (C) Quantification of pERK signal intensity with respect to total ERK (green line) and with 
respect to GAPDH (blue line) using ImageJ software. Fold change with respect to untreated time point is plotted on the y-axis and the 
phosphorylation state at untreated state is indicated by the red dotted line. (D) Graphical representation of the treatment scheme used for 
the inhibition of ERK signalling pathway during EMT. NMuMG cells were treated with an ERK inhibitor (UO126) 30 minutes before 
TGF-β stimulation. (E) Representative immunoblots showing the phosphorylation state of ERK at 4h and 24h of TGF-β-induced EMT with 
(UO126) or without (DMSO) ERK inhibition in NMuMG cells. GAPDH and total ERK serve loading controls. (F) Phase contrast images 
of untreated NMuMG cells and cells treated for 24h with TGF-β in the presence (UO126) or absence (DMSO) of the ERK inhibitor. (G) 
Immunofluorescence microscopy analysis of changes in the localization and expression levels of marker proteins in cells treated as in (F). 
The staining was performed with antibodies against the epithelial markers E-cadherin and ZO-1 and the mesenchymal markers N-cadherin 
and with phalloidin to visualize the actin cytoskeleton. Scale bar, 100 μm, 63X magnification.
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Figure 2: ERK signalling is essential for gene expression reprogramming during EMT. (A) Scatter plot representing the 
variation contributed by the first two components from a principal component analysis performed on the transcriptomes from DMSO EMT 
time points (0h, 4h and 24h) and after ERK inhibition (ERKi 4h and ERKi 24h). The first two principal components (PCs) are represented as 
distance on the x- and y-axis and represent the variation between the samples. (B-C) Volcano plots representing the differential expression 
of genes in 4h DMSO and 4h ERKi conditions (B) and 24h DMSO and 24h ERKi conditions (C). (D) UCSC Genome Browser track 
expression plot of the epithelial gene Nid2 for all afore mentioned conditions. (E) Bar plot depicting the expression of epithelial marker 
genes during all time points of DMSO EMT and after ERK inhibition. Significance was calculated using T-Test (* p<0.05; ** p<0.01; 
***<0.001). (F-G) The same as (D) and (E) but for mesenchymal genes. (H) Heatmap representation at all time points for the clusters 
generated by k-means clustering of differentially expressed genes between 4h of DMSO and 4h of ERKi. (I) Boxplot representation of the 
clusters generated in (H) for their expression at all time points. (J) Gene ontology categories representing the clusters generated in (H).
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associated with the regulation of locomotion, cell motility 
and migration (Figure 2J, cluster 2) and include Hmga2, 
Il11, Sox9, Lamb1, Enc1, Itgb3, Jag1 and Col1a1, which 
are reported to be essential for the acquisition of a 
mesenchymal phenotype.
The remaining clusters did not show a 
transcriptional reversal in an ERK-dependent manner 
and the genes within these clusters did not associate 
with EMT-relevant GO-terms. Cluster 3 included genes 
that were strongly induced by ERK inhibition and were 
associated with GO terms such as inflammatory response, 
response to bacteria and regulation of cell death (Figure 
2J, cluster 3), whereas cluster 5 comprised genes that 
were strongly downregulated in the ERK-inhibited 
condition and were associated with the regulation of 
MAPK signalling and numerous ribosome-associated 
GO terms (Figure 2J, Cluster 5). These two clusters 
probably represent secondary effects on gene expression 
as a result of the inhibitor treatment and most probably 
contain genes that are not directly related to EMT biology. 
For a comprehensive view of the transcriptional changes 
that occur during EMT and depend on ERK signalling, 
we performed the same analysis for the genes that 
were differentially expressed at 24h (Supplementary 
Figure 2-3). However, as shown by the derived clusters 
(Supplementary Figure 2A), the results did not show an 
increase in the essential informative clusters (cluster 2, 
3 and 6) but rather seemed to capture more secondary 
effects that were independent of the transcriptional 
reversal towards an untreated fate (cluster 1, 4 and 5), 
although we did capture a few more essential genes that 
exhibited transcriptional reversal, such as Snai1, Mmp9 
and Hnf4a. In summary, we identified a substantial set of 
EMT-relevant genes that display transcriptional induction 
or repression in an ERK-dependent manner during EMT, 
which is required for the phenotypic changes during this 
process.
ERK signalling mediates global epigenetic 
reprogramming during EMT
Intrigued by the ERK-dependent transcriptional 
reprogramming, we next investigated whether these 
changes can be explained by the influence of ERK on 
epigenetic remodelling during EMT. Active regulatory 
elements, such as promoters and enhancers are accessible 
and marked by acetylation of lysine 27 at Histone H3 
(H3K27ac), thereby allowing to study the activity state 
of both proximal and distal regulatory elements [21–23]. 
We therefore performed, a genome-wide analysis using 
ChIP-seq for H3K27ac at different time points of TGF-
β-induced EMT in normal and ERK-inhibited conditions. 
The genomic distribution confirmed the enrichment 
of the H3K27ac at promoters and potential enhancers, 
which are primarily situated in intergenic and intronic 
regions (Figure 3A). A comparative analysis of H3K27ac 
peaks did not show differences in the overall numbers 
of peaks (Figure 3A). We next examined local changes 
at specific sites. An inspection of tracks in the UCSC 
Genome Browser for the H3K27ac mark at promoter and 
non-promoter regions revealed that epithelial (Nid2 and 
Wnt4) and mesenchymal (Jak and Itga2) genes displayed 
ERK-dependent H3K27ac remodelling accompanying the 
transcriptional changes (Figure 3B–3E).
To further unravel the ERK-dependent H3K27ac 
dynamics that occur during normal and ERK-inhibited 
EMT and uncover whether chromatin changes might 
explain the observed gene expression changes, we further 
analysed the H3K27ac dynamics at promoters and distal 
regulatory sites that were differentially expressed between 
cells undergoing normal and ERK-inhibited EMT after 
4h (Figure 3F–3M). Interestingly, we observed a strong 
effect of ERK inhibition on the overall H3K27ac levels 
at all regions, a result in agreement with the observed 
transcriptional response (Figure 3F–3I). To predict whether 
these ERK-dependent H3K27ac changes might explain the 
phenotypic reversal towards an untreated state after ERK 
inhibitor treatment, we performed k-means clustering to 
assess the dynamics of H3K27ac at promoters and non-
promoter regions for the genes that were deregulated at 
4h (Figure 3J–3M). Similarly to our observations for gene 
expression, various clusters were found in all conditions 
that exhibited reversed H3K27ac status along with the 
expression changes for which they were selected, thus 
suggesting that ERK signalling is required for H3K27ac 
remodelling during EMT and thereby partially explains the 
ERK-dependent transcriptome remodelling. By analysing 
the promoters of genes that were upregulated at 4h of 
ERK-inhibited EMT induction, we found that clusters 3 
and 4 exhibited decreased H3K27ac levels during normal 
EMT but reverted towards levels observed in epithelial 
cells in the ERK-inhibited condition. These clusters 
contained epithelial genes, such as Wnt4, Id3 and Cldn9 
(Figure 3J). Moreover, in the analysis of the promoters 
of genes that were downregulated in ERK-inhibited EMT 
at 4h, the genes in clusters 1 and 2 displayed increased 
H3K27ac levels during normal EMT but not after ERK 
inhibition (Figure 3K). Strikingly, these clusters contained 
EMT-relevant genes, such as Hmga2, Il11, Itga2, Tgfbr1 
and Lamb1, which also exhibited transcriptional reversal 
(Supplementary Figure 4A).
Because the number of EMT-relevant differentially 
expressed genes that could be explained by an ERK-
dependent H3K27ac dynamic at promoters was limited, 
we explored whether distal H3K27ac sites might regulate 
the remaining set of EMT-relevant changes that occur after 
ERK inhibition. In this analysis, at non-promoter regions 
of genes that were upregulated after ERK inhibition at 
4h, we found that clusters 1 and 2 (n=149 and n=271 
regions, respectively) exhibited decreased H3K27ac levels 
during normal EMT but not after ERK inhibition (Figure 
3L). These potential enhancer elements that exhibited a 
more epithelial-like H3K27ac level after ERK inhibition 
were associated with genes that are critical for epithelial 
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Figure 3: ERK pathway impacts upon H3K27ac dynamics during EMT. (A) Bar plots represent the genome-wide peak 
distribution of the H3K27ac sites. (B, D) UCSC Genome Browser tracks representing H3K27ac enrichment and expression levels at 
promoters (B) and non-promoters (D) of epithelial marker genes in all conditions. (C, E) UCSC Genome Browser tracks representing 
H3K27ac enrichment and expression level at promoters (C) and non-promoters (E) of mesenchymal marker genes in all conditions. (F) 
Box plot represents the H3K27ac dynamics for the promoters of URGs with p-value cross correlation plot for each of these time points. (G) 
Box plot represents the H3K27ac dynamics for the promoters of DRGs with p-value cross correlation plot for each of these time points. 
(H) Box plot represents the H3K27ac dynamics for the non-promoters of URGs with p-value cross correlation plot for each of these time 
points. (I) Box plot represents the H3K27ac dynamics for the non-promoters of DRGs with p-value cross correlation plot for each of these 
time points. (J) Heatmap of H3K27ac dynamics at all time points at promoter regions of URG-representing clusters generated by k-means 
clustering. (K) Heatmap of H3K27ac dynamics at all time points at promoter regions of DRG-representing clusters generated by k-means 
clustering. (L) Heatmap of H3K27ac dynamics at all time points at non-promoter regions of URG-representing clusters generated by 
k-means clustering. (M) Heatmap of H3K27ac dynamics at all time points at non-promoter regions of DRG-representing clusters generated 
by k-means clustering. (N) Venn diagram representing the overlap of cluster 1 from 4h DEGs (Figure 2H) with clusters 3 and 4 from URG 
promoters and clusters 1 and 2 from URG non-promoters. (O) Venn diagram representing the overlap of clusters 2 and 4 from 4h DEGs 
(Figure 2H) with clusters 1 and 2 from DRG promoters and cluster 3 from DRG non-promoters.
DRG: Downregulated genes in ERKi condition versus DMSO; URG: upregulated genes in ERKi condition versus DMSO; DEG: 
Differentially expressed genes in ERKi condition versus DMSO.
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biology, such as Cmtm8, Wnt4 and Shroom3. Moreover, 
these genes also showed expression level reversal after 
ERK inhibition (Supplementary Figure 4B) and might 
therefore be regulated by distal regulatory regions. The 
genes nearest to these potential enhancers were strongly 
associated with signalling pathways and apoptosis as 
well as with tissue development, response to wounding, 
positive regulation of cell communication and epithelial 
cell development, thus suggesting their importance 
in epithelial biology (Supplementary Figure 4C). An 
inspection of H3K27ac kinetics at non-promoter regulatory 
regions of genes downregulated at 4h of ERK-inhibited 
EMT revealed that cluster 3 (n=367 regions) exhibited 
substantial H3K27ac enrichment during normal EMT but 
reverted towards epithelial status in the ERK-inhibited 
condition (Figure 3M). These potential enhancers were 
located close to mesenchymal state-promoting genes, such 
as Il11, Hmga2, Lamb1, Jag1 and Itgb3 (Supplementary 
Figure 4D), which also exhibited downregulated 
expression levels after ERK inhibition. GO terms for these 
genes were associated with many signalling cascades, 
including the MAPK cascade and EMT-relevant processes, 
such as cell migration, locomotion, gastrulation and cell 
motility (Supplementary Figure 4E), thus suggesting the 
potential for ERK-dependent enhancer activation, which 
leads to a gain in H3K27ac status during EMT. Having 
observed gene clusters that were essential for maintaining 
epithelial cell-like expression patterns in ERK-inhibited 
EMT (Figure 2H) and might explain the failure of cells 
to undergo proper EMT, we sought to determine the 
proportion of these genes whose expression changes could 
be explained by H3K27ac patterns either at promoters 
or potential enhancer elements. For the genes that were 
essential for epithelial biology and downregulated 
during normal EMT but not when ERK signalling was 
compromised (Figure 2H, cluster 1), almost all genes 
exhibited a reverted H3K27ac pattern either at promoters 
(~55%), potential enhancers (~78%) or both (~42%), 
thus suggesting that ERK-dependent transcriptional 
remodelling is consistent with epigenetic changes (Figure 
3N). Similarly, more than half (60%) of the mesenchymal 
genes that were transcriptionally induced during EMT 
in an ERK-dependent manner (Figure 2H, cluster 2 and 
4) also showed a reverted H3K27ac pattern at promoters 
(~36%), enhancers (~50%) or both (~27%) (Figure 3O).
ERK-dependent epigenetic reprogramming 
contributes to transcriptional changes during 
EMT
Since ERK signalling was found to be essential 
for a subset of the transcriptional and epigenetic changes 
that accompany normal EMT, we performed a more 
comprehensive investigation of the association between 
the H3K27ac and transcriptome changes during EMT 
and their dependence on ERK signalling (Figure 4A). 
Thus, we examined the global H3K27ac changes between 
normal and ERK-inhibited EMT at 4h in promoter and 
non-promoter regions at genes that were differentially 
expressed under these conditions (Figure 4B and 4C, 
Supplementary Figure 5A). Strikingly, we observed a 
very strong correlation at promoters and non-promoters, 
thus suggesting that ERK-dependent transcriptional 
remodelling is linked to H3K27ac dynamics. Whereas a 
small set of genes displayed ERK-dependent regulation 
of H3K27ac at their promoters (number of genes (G) = 
68), a far larger set of genes (G=262) was regulated by 
H3K27ac changes at potential enhancer regions (number 
of regions (R) =639), thus suggesting that ERK signalling 
affects gene regulation via enhancer regulation. To extract 
the subset of such regions that might explain the observed 
epithelial phenotype of cells during ERK-inhibited 
TGF-β-induced EMT, we selected the set of regions that 
exhibited significantly induced or suppressed H3K27ac 
levels during normal EMT and reverted in both H3K27ac 
and expression towards an epithelial state in ERK-
compromised EMT (Figure 4A). Strikingly, even though 
these regions were selected from the 4h time point, the 
reversal was equally strong and highly significant at both 
4h and 24h (Figure 4D and 4E, Supplementary Figure 5B 
and 5C). This finding clearly indicates that such regions 
are important not only at the onset of EMT but also at later 
time points, when the cells are in a more mesenchymal 
state. The gene ontology categories that were enriched 
for the genes that lost expression and H3K27ac levels at 
their nearest potential enhancer during EMT in an ERK-
dependent fashion relate to epithelial cell development, 
mammary gland epithelial development, several signalling 
and metabolic processes (Figure 4F). These results suggest 
that these genes are important in epithelial biology and 
the tuning of signalling and metabolism during cell fate 
change. The genes that gained expression and enhancer 
H3K27ac levels in an ERK-dependent manner during 
EMT were enriched in GO terms associated with cell 
migration, motility, locomotion and wound healing, 
thus indicating their involvement in the acquisition of 
a mesenchymal, motile phenotype. In addition, several 
metabolic and signalling GO terms were also enriched 
that again relate to different requirements during cell fate 
changes (Figure 4G).
Next, we sought to predict transcription factors that 
may function at distal genomic sites that are epigenetically 
remodelled during EMT and contribute to gene expression 
changes. Therefore, we performed a motif prediction at the 
distal regions that exhibited reverted H3K27ac levels and 
examined the expression of the predicted binding factors 
during normal EMT (Figure 4H–4I and Supplementary 
Figure 5D-5E). This analysis revealed the genes that 
were downregulated during EMT in an ERK-dependent 
fashion might be directly acted upon by FOXA2, HIF2A 
and FOXP1, all of which are expressed at the relevant 
time point at 4h of EMT (Figure 4H and Supplementary 
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Figure 4: ERK-dependent chromatin changes contribute to transcriptional reprogramming during EMT. (A) Scheme 
representing the strategy for downstream analysis. (B) Correlation of H3K27ac dynamics and gene expression at promoter regions (n1, n2, 
n3, n4 represent the number of significant H3K27ac sites at the respective gene). (C) Correlation of H3K27ac dynamics and expression 
of the nearest gene at non-promoter regions (n1, n2, n3, n4 represents the number of significant H3K27ac sites at differentially expressed 
genes). (D) Boxplot representing the significantly regulated non-promoters sites of URG in 1) the normal EMT time course between 0h 
and 24h and 2) between the 4h time points of ERKi and DMSO, with p-value cross correlation plots for each of these conditions below. (E) 
Boxplot representing the significantly regulated non-promoters sites of DRG in 1) the normal EMT time course between 0h and 24h and 
2) between the 4h time points of ERKi and DMSO, with p-value cross correlation plots for each of these conditions below. (F) GO terms 
for the URGs that significantly changes 1) between ERKi 4h and DMSO 4h and 2) in the normal EMT time course between 0h and 24h. 
(G) GO terms for the DRGs that significantly changes 1) between ERKi 4h and DMSO 4h and 2) in the normal EMT time course between 
0h and 24h DMSO. (H) Plot representing the motifs enriched at non-promoter sites of URGs. (I) Plot representing the motifs enriched 
at non-promoter sites DRGs. (J) Model showing ERK dependent epigenetic reprogramming during EMT: During TGF-β induced EMT, 
ERK signalling becomes activated and in turn phosphorylates downstream effectors including transcription factors (TFs) that translocate 
into the nucleus and establish gene expression program required for EMT. Such activating and repressing transcription factors interact 
with members of the epigenetic machinery (EM) to set up chromatin landscape changes at promoters and enhancer elements to activate 
mesenchymal and repress epithelial genes.
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Figure 5D). For the genes that were upregulated during 
EMT in an ERK-dependent manner, we identified ETS1, 
FOSL2, FOSL1, ATF3, JUN, GABPA, RUNX1, ELK1 
and ATF2, which were also all expressed at the relevant 
EMT time point, thus suggesting that they are potential 
downstream factors of ERK signalling that function at 
these regions (Figure 4I and Supplementary Figure 5E). 
Overall, we identified a distinct set of EMT-relevant genes 
that undergo epigenetic and transcriptional reprogramming 
in an ERK-dependent manner and further predicted the 
downstream effectors that may mediate these responses.
DISCUSSION
Epithelial to mesenchymal transition allows cells 
to migrate and therefore, it is a key process during 
development, wound healing, fibrosis and cancer 
metastasis. The phenotypic remodelling can be initiated 
by several signalling molecules that activate a plethora 
of downstream signalling cascades. A prototypic inducer 
of EMT is TGF-β, which is known to activate both the 
canonical Smad signalling pathway and several non-
canonical pathways, including MAPK signalling. 
Although the interplay of several pathways has become 
increasingly clear and key EMT genes, such as Snail Twist 
and Zeb1 have been identified, the transcriptional networks 
induced by each pathway remain poorly understood. 
Here, we delineated the global transcriptional response 
during TGF-β-induced EMT in a model system of mouse 
mammary gland epithelial cells (NMuMG) and further 
narrowed the fraction of transcriptional responses that are 
dependent on ERK signalling by using an established ERK 
inhibitor. Strikingly, we observed that cells inhibited for 
ERK signalling shortly before TGF-β induction failed to 
undergo proper EMT and are retained in an epithelial state 
as further reflected by the phenotype and transcriptome 
analysis. Our results suggest that ERK signalling is 
critical for the onset of EMT given its induction at early 
stages of TGF-β induced EMT and observations that 
its inhibition compromises molecular and phenotypic 
changes required for acquiring mesenchymal identity. In 
light to our earlier findings where we showed that JNK 
signalling is inducted at later time points during EMT and 
is essential for progression of EMT but not its onset [20]. 
Such differences in induction kinetics of several EMT-
relevant signalling pathways vouches for a comprehensive 
analysis to decipher how such networks collaboratively 
induce consecutive steps of TGF-β induced EMT and how 
this involves coordinated regulation of gene regulatory 
programs underlying EMT.
ERK inhibition led to failure of cells to induce 
critical EMT genes, such as Il11, Snai1, Hmga2, Sox9 
and Lamb1. Moreover, the downregulation of key 
epithelial genes, such as Cdkn1a, Id2, Tjp3, Crb3 and 
Wnt4, was compromised, thus suggesting that active 
ERK signalling is essential for such transcriptional 
responses driving EMT. Interestingly, we also observed 
that the transcriptional response in ERK-inhibited cells 
at the late time point (24h) was more similar to that of 
the untreated condition (0h). We further examined the 
transcriptional dynamics during EMT and the dependence 
of early- versus late-induced transcriptional changes on 
ERK signalling. Interestingly, we clearly identified a set 
of ERK-dependent genes that were most strongly induced 
at 4h of EMT and were not highly activated at later time 
points. These genes had functions in locomotion and cell 
motility but displayed an overrepresentation of metabolic 
processes and signalling cascades, thus suggesting that 
the early changes strongly regulate the altered metabolic 
needs of cells that migrate out of connected tissues and 
the induction of secondary signalling cascades that 
transmit the original signal. The class of genes strongly 
induced at later EMT time points (24h) did not show such 
overrepresentation of metabolic and signalling processes 
but were mostly related to motility, migration, locomotion 
and movement, thus supporting the acquisition of a 
motile mesenchymal phenotype. Overall, the most EMT-
relevant transcriptome changes were observed at the 
early time point (4h), while the later time point (24h) also 
included genes associated with cell cycle regulation as 
well as DNA metabolic processes in addition to few EMT 
relevant genes. This may simply reflect an accumulation 
of primary and secondary effects at later time points due to 
a prolonged inhibition of ERK signalling, where we may 
also start to see influence of inhibiting its known function 
in cellular proliferation [24] [25] [26].
A body of emerging evidence suggest that the fast 
integration of extracellular cues is essentially achieved 
by signalling cascades directly affecting chromatin 
and thereby ensuring a fast and precise transcriptional 
response [10]. Although the importance of epigenetic 
remodelling during cell fate changes is well known, 
genome-wide studies for chromatin alterations during 
EMT are sparse, and they have not focused on the effects 
of one particular signalling pathway on epigenomic 
changes [11]. Therefore, we chose to analyse the ERK 
signalling-dependent remodelling of the active chromatin 
mark H3K27ac, which is present at active promoters 
and enhancers, at different time points during TGF-β-
induced EMT. Strikingly, we found that a large proportion 
of EMT-relevant genes that were transcriptionally 
regulated during EMT in an ERK-dependent manner 
associated with promoters or enhancer elements that 
displayed ERK-dependent remodelling of this chromatin 
mark. Therefore, we were able to show that a significant 
fraction of H3K27ac sites at promoters and intergenic 
regions become remodelled partly in an ERK-dependent 
fashion during EMT. This study thus provides the first 
description of an enhancer landscape that is remodelled 
in an ERK dependent manner during EMT and regulates 
the silencing of epithelial genes, such as Wnt4, Cmtm8, 
Shroom3 and the activation of mesenchymal genes, 
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such as Hmga2, Il11, Itga2, Tgfbr1 and Lamb1. While 
these genes we exemplified have been established to be 
important for epithelial or mesenchymal identity, our study 
uncovers the regulatory elements that potentially function 
to control their expression and further offers a basis for 
investigation into the molecular players operating at these 
regions in their transcriptional regulation.
Since previous studies in mouse and human 
embryonic stem cells [16] demonstrated direct binding of 
ERK to chromatin [17, 18] we had also tested whether 
ERK directly binds chromatin during different stages 
of EMT. However, our attempts to do ChIP-seq assay 
using several endogenous antibodies as well as following 
overexpression of tagged versions of ERK1 and ERK2 
during EMT showed no reliable binding sites (data not 
shown). Therefore, at least in the context of EMT, ERK 
does not function by a direct binding to chromatin and 
may exclusively employ downstream factors to mediate 
epigenetic reprogramming. To predict such factors we 
performed motif analysis at genomic regions losing and 
gaining H3K27ac that indicated the enrichment of a 
distinct set of transcription factors, many of which are 
known to be involved in EMT [27–30]. These factors 
offer ideal candidates for further mechanistic investigation 
of their function downstream of ERK in driving the 
observed epigenetic and transcriptional responses. To 
extend these findings, future work should also involve 
generating a phospho-proteome with and without 
ERK inhibition at early EMT time points to unravel 
transcription factors that are phosphorylated in an ERK-
dependent manner during onset of EMT.
Overall, our data provide the first delineation of 
early and late transcriptional responses during TGF-β-
induced EMT that rely on ERK signalling and relate 
these changes to the epigenetic reprogramming of the 
active regulatory landscape. These data further uncover 
distinct transcription factors that function downstream of 
ERK and cooperate with epigenetic machinery to mediate 
epigenetic reprogramming at regulatory elements of EMT-
relevant genes (Figure 4J). Given these evidences for 
ERK signalling mediated chromatin remodelling to drive 
transcriptional program underlying EMT, it is desirable 
to gain a comprehensive understanding of the involved 
players and kinetics of these processes. Furthermore, it 
would be essential to validate the generality of our findings 
to different contexts of EMT such as gastrulation [31, 32], 
neural crest formation [33], tissue regeneration and wound 
healing [3, 4], as well as pathogenic conditions such as 
fibrosis [5] and metastasis formation during tumorigenesis 
[6] [34]. Deciphering these mechanisms will allow us to 
uncover the basic principles of gene regulation driving cell-
fate changes, at the same time offer possibility to reveal 
novel therapeutic avenues for the treatment of disorders 
involving aberrant EMT, such as cancer.
MATERIALS AND METHODS
Cell culture
For our study we used a subclone of NMuMG cells 
(NMuMG/E9, hereafter NMuMG) that has been described 
previously [19] and was grown in DMEM supplemented 
with 10% FBS, 2 mM L-Glutamine and 1X Non-essential 
amino acids and cultured at 37°C with 7% CO2 in a humid 
incubator. For EMT induction, NMuMG cells were treated 
with 2 ng/ml TGF-β (rhTGF-β1 240-B, R&D systems) for 
the indicated time points.
Inhibitor treatment
Cells were seeded at same densities and pretreated 
30 min prior to TGF-β treatment with ERK-signaling 
inhibitors UO126 (25μM) and PD98095 (50μM) or 
their solvent DMSO and were subjected to respective 
experiments and analyzed at indicated time points.
Immunofluorescence assay
NMuMG cells were grown on coverslips, fixed with 
4% paraformaldehyde in PBS and permeabilized with 
0.2% Triton X-100 for 15 minutes at room temperature. 
Subsequently, cells were blocked for 20 minutes at room 
temperature in blocking solution (10% goat serum, 5% 
FCS and 0.5% BSA in PBS) followed by incubation with 
primary antibodies at 4°C overnight. These samples were 
washed three times with PBS for 10 minutes at room 
temperature following incubation with fluorochrome-
labeled secondary antibody or Phalloidin-633 as well as 
Hoechst for DNA counterstain (20ng/ml) for 1 hour at 
room temperature. For mounting of the samples Immu-
Mount (Thermo Scientific) reagent was used and samples 
were imaged with a confocal laser-scanning microscope 
(SP05, Leica). Data were processed with ImageJ software.
Antibodies used for immunofluorescence 
were E-Cadherin (13-1900, Invitrogen and 610182, 
BDTransduction Laboratories), N-Cadherin (610921, BD 
Transduction Laboratories), ZO-1 (617300, Invitrogen), 
Alexa Fluor-488 goat anti mouse IgG (H+L) (A11029, 
Invitrogen); Alexa Fluor-568 goat anti rabbit IgG (H+L) 
A11011 Invitrogen; and Alexa Fluor-633 goat anti rat IgG 
(H+L) A21094, Invitrogen, Alexa Fluor 633 Phalloidin 
(A22284, Invitrogen) was used to stain F-actin.
RNA extraction
RNA was extracted using the SurePrep TrueTotal 
RNA Purification Kit (Fisher Scientific) according to 
manufactures instructions.
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Immunoblotting
Cells were lysed in RIPA buffer (50mM Tris (pH8), 
1%NP40, 0.5% sodium deoxycholate, 0.1%SDS, 150mM 
NaCl, 5mM EDTA, 1% Glycerol, 2.5mM MgCl, 2mM 
sodium orthovanadate) and protein concentrations were 
quantified by using Bradford reagent (Biorad). Equal 
amounts of proteins (30 μg) were boiled in 6 × SDS–
PAGE loading buffer and run on a polyacrylamide gel 
and transferred to a PVDF membrane and probed with 
respective antibodies.
Antibodies used for immunoblotting were 
Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) 
Antibody #9101, Erk1/2 (sc94, santa cruz) and GAPDH 
(221-MG-GAPDH, Immuno Kontact).
ChIP assay
NMuMG cells were cross-linked in growth 
medium containing 1% formaldehyde for 10 min at room 
temperature, neutralized with 0.125M glycine, scraped off 
and rinsed twice with 10 ml 1X PBS. The fixed cells were 
subjected to preparation of nuclear lysates. In detail pellets 
were resuspended in 3 mL of Buffer L1 (50mM Hepes 
KOH, pH 7.5, 140mM NaCl, 1mM EDTA pH 8.0, 10% 
glycerol, 5% NP-40, 0.25% Triton-X 100) and incubated 
for 10 min at 4°C. This was followed by centrifugation for 
5 min at 4°C at 1300g. The pellet was then resuspended 
in 3 ml of Buffer L2 (200mM NaCl, 1mM EDTA pH 8.0, 
0.5mM EGTA pH 8.0, 10mM Tris pH 8.0) and incubated 
for 10 min at room temperature, followed by centrifugation 
for 5 min at 4°C at 1300g. The pellet was then resuspended 
in 600 μl Buffer L3 (1mM EDTA pH 8.0, 0.5mM EGTA 
pH 8.0, 10mM Tris pH 8.0, 100mM NaCl, 0.1% Na-
deoxycholate, 0.17mM N-Lauroyl sarcosine) containing 
protease inhibitors and incubated at 4°C for 3 hours 
following sonication using Bioruptor plus (Diagenode). 60 
μg of chromatin was incubated overnight at 4 °C with 2 
μg of the antibody targeting H3K27ac (ab4729; Abcam) 
to allow formation of the immunocomplex. To pull down 
H3K27ac enriched DNA fragments the mixture was 
then incubated for 3 h with 40 μl protein A-Sepharose 
beads preblocked with tRNA and BSA at 4°C. To reduce 
background signal these beads were subjected to several 
washing steps employing different buffers. For this beads 
were washed twice with 1 ml buffer L3 and once with 1 
ml DOC buffer (10 mM Tris (pH 8.0), 0.25 M LiCl, 0.5% 
NP-40, 0.5% deoxycholate, 1 mM EDTA) and transferred 
to a fresh Eppendorf tube using TE buffer. The bound 
chromatin was eluted in 1% SDS/0.1 M NaHCO3 in 
two rounds for 20 minutes and eluates were combined. 
The eluate containing the immunocomplex bound to the 
precipitated DNA was treated with RNase A (0.2mg/ml) 
for 30 min at 37°C and then with proteinase K (50 μg/
ml) for 2.5 h at 55°C. The crosslinking was reversed at 
65°C overnight with gentle shaking and precipitated DNA 
was purified by phenol-chloroform extraction followed by 
ethanol precipitation and recovered in 40 μl TE buffer.
RNAseq data analysis
RNA sequencing for untreated (0hr), 4hr, 24hr time 
points under DMSO and ERK inhibition conditions were 
performed. After receiving RNA sequencing output in 
fastq format, quality check was performed using FASTQC 
version v0.10.0 followed by alignment using TopHat 
version v2.0.8 [35] to the mouse genome (mm9) with 
default parameters. Mapping reads were considered for 
read count per gene using HTSeq version 0.5.4p1 [36]. 
Output from HTSeq (Read counts) were normalized and 
differential gene expression analysis was performed using 
a R package DESeq with FDR rate of 0.1 [37]. Differential 
expression analysis between 4hr time point from DMSO 
and ERK inhibited conditions were performed. Similar 
analysis was also performed for 24hr time point. GO 
(Gene Ontology) analysis of the Differentially expressed 
genes was performed using ToppGene [38].
H3K27ac ChIP-seq analysis
H3K27ac ChIP-seq was performed for the 0hr, 4hr 
and 24hr time points under the DMSO and ERK inhibition 
conditions. After quality check using FASTQC version 
v0.10.0 sequencing reads were aligned to reference mouse 
genome (mm9) using bowtie version 0.12.9 [39] with 
default parameters. Output obtained after alignment (.sam) 
converted to .bam using samtools version: 0.1.19-44428cd 
[40]. MACS2 version 2.0.10.20120913 [41] was used for 
peak calling with default parameters. Called peaks from 
each samples containing replicates were merged together 
for the peak reproducibility. Raw enrichment for each 
merged sample with respect to input was calculated by using 
bam file from replicates for each condition using QuasR 
package [42]. Further, Normalized Enrichment with respect 
to input for each of the condition was calculated. Peak 
displaying 1.5 fold enrichment above input were selected 
for subsequent analysis. All the significantly enriched peaks 
were categorized into promoter and non-promoter peaks. 
The peaks regulating the differentially regulated genes at 4hr 
conditions were screened and used for the further analysis.
Browser track generation
Wig files were created for all the samples using 
QuasR package [42] and visualized using UCSC genome 
browser.
Genome wide peak distribution
The gene annotation file for mouse (mm9) from 
UCSC was used and the peaks were annotated using 
HOMER utility [43] annotatePeaks.pl, which gives 
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the information of the number of peaks present at the 
promoter, intergenic regions, exon, intron and UTRs.
Motif analysis
Motif Analysis was performed for distal regulatory 
elements using Homer utility [43] on the regions 
significantly regulated during 4hr conditions (i.e. 4hr 
DMSO and 4hr ERK inhibition) and untreated to 24hr 
DMSO condition by 1.25 fold.
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